Schizophrenia Genetic Risk Linked to Mitochondrial Dysfunction

Rutgers University Researchers at Rutgers and Emory University are gaining insights into how schizophrenia develops by studying the strongest-known genetic risk factor. When a small portion of Chromosome 3 is missing – known as 3q29 deletion syndrome – it increases the risk for schizophrenia by about 40 fold. Researchers have now analyzed overlapping patterns of altered gene activity in two models of 3q29 deletion syndrome, including mice where the deletion has been engineered in using CRIPSR, and human brain organoids, or three-dimensional tissue cultures used to study disease. These two systems both exhibit impaired mitochondrial function. This dysfunction can cause energy shortfalls in the brain and result in psychiatric symptoms and disorders. “Our data give strong support to the hypothesis that mitochondrial dysregulation is a contributor to the development of schizophrenia,” said Jennifer Mulle, associate professor of psychiatry, neuroscience and cell biology at Rutgers Robert Wood Johnson Medical School and a co-senior author of the study published in Science Advances. “The interplay between mitochondrial dynamics and neuronal maturation is an important area for additional detailed and rigorous study.” Mulle, a member of the Center for Advanced Biotechnology and Medicine at Rutgers, and colleagues first showed that 3q29 deletion was a risk factor for schizophrenia in 2010. The findings converge with work on another genetic risk factor for schizophrenia, 22q11 deletion syndrome (or DiGeorge syndrome), which has also been found to involve disrupted mitochondrial function. “For genetic variants associated with schizophrenia, we want to understand the primary pathology at the cellular level,” said Ryan Purcell, assistant professor of cell biology at Emory University School of Medicine and co-lead author of the study. “This gives us a foothold, which may help cut through schizophrenia’s polygenic complexity and better understand the neurobiology.” About one in 30,000 people are born with 3q29 deletion syndrome. In addition to increasing the risk for schizophrenia, 3q29 deletion can include intellectual disability, autism spectrum disorder and congenital heart defects. The effect of 3q29 deletion on schizophrenia risk is more than any single known gene variant, but the contributions of individual genes within the deletion are still being unraveled. The finding that various schizophrenia-associated chromosomal deletions impair mitochondria runs counter to an expectation in the field that such mutations should alter proteins in the synapses that connect neurons. However, mitochondria are critical for energy-hungry synapses’ function – so these models may not be in conflict. It was also surprising that 3q29 cells have poorly functioning mitochondria because only one of the 22 genes in the deletion appears to encode a protein located in mitochondria. However, that gene or others within the interval may instead regulate the production or importation of mitochondrial proteins, the researchers said. Mitochondria, which are found in every cell, produce energy from sugar or fat. Sometimes this process is aerobic (done with extra oxygen from inhaled air) and sometimes anaerobic (done without oxygen). As a result of altered mitochondrial function, 3q29 cells lack metabolic flexibility, meaning their mitochondria have difficulty adapting to changes in sources of energy. This may interfere with neuronal development because maturing neurons need to switch to relying on aerobic energy production as they differentiate. The results illustrate how 3q29 deletion affects the whole body, not just the brain: The effects on mitochondria are seen in kidney cells as well as in brain cells. Individuals with 3q29 deletion syndrome also tend to be smaller in size, possibly because of altered fat metabolism. “Eventually, we want to understand which cellular changes like these are linked to specific clinical outcomes, which could help in designing more effective therapeutic strategies,” Purcell said. /Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.

Global Facial Implant Market Fueled by Rising Virtual Representation on Social Media – Forecast 2023-2030

DUBLIN, Aug. 16, 2023 /PRNewswire/ — The “Global Facial Implant Market by Product (Cheek, Chin & Mandibular, Injectables), Material (Biologicals, Ceramic, Metal), Procedure – Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation – Forecast 2023-2030” report has been added to ResearchAndMarkets.com’s offering. The Global Facial Implant Market size was estimated at USD 3.29 billion in 2022, USD 3.62 billion in 2023, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.52% to reach USD 7.32 billion by 2030. The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Facial Implant Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange. Market Segmentation & Coverage: This research report categorizes the Global Facial Implant Market in order to forecast the revenues and analyze trends in each of following sub-markets: Based on Product, the market is studied across Cheek, Chin & Mandibular, Injectables, and Nasal. The Chin & Mandibular is projected to witness significant market share during forecast period. Based on Material, the market is studied across Biologicals, Ceramic, Metal, and Polymers. The Ceramic is projected to witness significant market share during forecast period. Based on Procedure, the market is studied across Eyelid Surgery, Facelift, and Rhinoplasty. The Eyelid Surgery is projected to witness significant market share during forecast period. Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The report provides insights on the following pointers: Market Penetration: Provides comprehensive information on the market offered by the key players Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments The report answers questions such as: What is the market size and forecast of the Global Facial Implant Market? What are the inhibiting factors and impact of COVID-19 shaping the Global Facial Implant Market during the forecast period? Which are the products/segments/applications/areas to invest in over the forecast period in the Global Facial Implant Market? What is the competitive strategic window for opportunities in the Global Facial Implant Market? What are the technology trends and regulatory frameworks in the Global Facial Implant Market? What is the market share of the leading vendors in the Global Facial Implant Market? What modes and strategic moves are considered suitable for entering the Global Facial Implant Market? Market Dynamics Drivers Rising virtual representation on social media Growing concern regarding personal appearance among population Increasing cases of facial deformities due to congenital disorders Restraints Huge cost associated with facial implants Opportunities Increasing investments in the R&D of biocompatible implant manufacturing Rising adoption of minimally invasive surgeries and presence of advanced healthcare infrastructure Challenges Complications associated with the surgeries Companies Mentioned AbbVie Eurosurgical Ltd. Galderma S.A. Guangzhou Wanhe Plastic Materials Co., Ltd. Implantech Matrix Surgical USA Medartis AG Ortho Baltic POLYTECH Health & Aesthetics GmbH Sebbin STEMart Stryker Corporation Suneva Medical PLC Surgiform Technologies LLC SurgiSil Technomed India Pvt. Ltd. Xilloc Medical Int B.V. For more information about this report visit https://www.researchandmarkets.com/r/75qvho About ResearchAndMarkets.comResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact:Research and MarketsLaura Wood, Senior Manager[email protected] For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716 Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg SOURCE Research and Markets

Study supports hypothesis that mitochondrial dysregulation is a contributor to the development of schizophrenia

Credit: Pixabay/CC0 Public Domain Researchers at Rutgers and Emory University are gaining insights into how schizophrenia develops by studying the strongest-known genetic risk factor. When a small portion of chromosome 3 is missing—known as 3q29 deletion syndrome—it increases the risk for schizophrenia by about 40-fold. Researchers have now analyzed overlapping patterns of altered gene activity in two models of 3q29 deletion syndrome, including mice where the deletion has been engineered in using CRIPSR, and human brain organoids, or three-dimensional tissue cultures used to study disease. These two systems both exhibit impaired mitochondrial function. This dysfunction can cause energy shortfalls in the brain and result in psychiatric symptoms and disorders. “Our data give strong support to the hypothesis that mitochondrial dysregulation is a contributor to the development of schizophrenia,” said Jennifer Mulle, associate professor of psychiatry, neuroscience and cell biology at Rutgers Robert Wood Johnson Medical School and a co-senior author of the study published in Science Advances. “The interplay between mitochondrial dynamics and neuronal maturation is an important area for additional detailed and rigorous study.” Mulle, a member of the Center for Advanced Biotechnology and Medicine at Rutgers, and colleagues first showed that 3q29 deletion was a risk factor for schizophrenia in 2010. The findings converge with work on another genetic risk factor for schizophrenia, 22q11 deletion syndrome (or DiGeorge syndrome), which has also been found to involve disrupted mitochondrial function. “For genetic variants associated with schizophrenia, we want to understand the primary pathology at the cellular level,” said Ryan Purcell, assistant professor of cell biology at Emory University School of Medicine and co-lead author of the study. “This gives us a foothold, which may help cut through schizophrenia’s polygenic complexity and better understand the neurobiology.” About one in 30,000 people are born with 3q29 deletion syndrome. In addition to increasing the risk for schizophrenia, 3q29 deletion can include intellectual disability, autism spectrum disorder and congenital heart defects. The effect of 3q29 deletion on schizophrenia risk is more than any single known gene variant, but the contributions of individual genes within the deletion are still being unraveled. The finding that various schizophrenia-associated chromosomal deletions impair mitochondria runs counter to an expectation in the field that such mutations should alter proteins in the synapses that connect neurons. However, mitochondria are critical for energy-hungry synapses’ function—so these models may not be in conflict. It was also surprising that 3q29 cells have poorly functioning mitochondria because only one of the 22 genes in the deletion appears to encode a protein located in mitochondria. However, that gene or others within the interval may instead regulate the production or importation of mitochondrial proteins, the researchers said. Mitochondria, which are found in every cell, produce energy from sugar or fat. Sometimes this process is aerobic (done with extra oxygen from inhaled air) and sometimes anaerobic (done without oxygen). As a result of altered mitochondrial function, 3q29 cells lack metabolic flexibility, meaning their mitochondria have difficulty adapting to changes in sources of energy. This may interfere with neuronal development because maturing neurons need to switch to relying on aerobic energy production as they differentiate. The results illustrate how 3q29 deletion affects the whole body, not just the brain: The effects on mitochondria are seen in kidney cells as well as in brain cells. Individuals with 3q29 deletion syndrome also tend to be smaller in size, possibly because of altered fat metabolism. “Eventually, we want to understand which cellular changes like these are linked to specific clinical outcomes, which could help in designing more effective therapeutic strategies,” Purcell said. More information: Ryan Purcell et al, Cross-species analysis identifies mitochondrial dysregulation as a functional consequence of the schizophrenia-associated 3q29 deletion, Science Advances (2023). DOI: 10.1126/sciadv.adh0558. www.science.org/doi/10.1126/sciadv.adh0558 Provided by Rutgers University Citation: Study supports hypothesis that mitochondrial dysregulation is a contributor to the development of schizophrenia (2023, August 16) retrieved 16 August 2023 from https://medicalxpress.com/news/2023-08-hypothesis-mitochondrial-dysregulation-contributor-schizophrenia.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Most infants admitted to ICU for RSV were previously healthy, study finds

Most infants admitted to the intensive care or high acuity unit for respiratory syncytial virus (RSV) infections during fall 2022 were previously healthy and born at term, according to a new study reported in JAMA Network Open. The findings from this study support the use of preventative interventions in all infants to protect them from RSV, the leading cause of lower respiratory tract infections (LRTI) and hospitalizations worldwide. RSV accounts for about 57,000-80,000 hospitalizations in children younger than 5 years with 1 in 5 RSV-positive hospitalized children being admitted to intensive care units, according to the Centers for Disease Control and Prevention (CDC). Researchers across the United States evaluated the characteristics and outcomes of RSV-related critical illness in 600 infants from 39 hospitals across 27 states as part of the RSV Pediatric Intensive Care registry. The registry conducted prospective surveillance during the RSV seasonal peak in 2022. During the two-month period, the investigators found: The median age for infants requiring intensive care was 2.6 months. 169 (28%) were premature. 487 (81%) had no underlying medical conditions. 143 (24%) received invasive mechanical ventilation. “Most of the infants in our study receiving ICU-level care were young, healthy and born at term,” said lead investigator Natasha Halasa, MD, MPH, Craig Weaver Professor of Pediatrics in the Division of Pediatric Infectious Diseases at Monroe Carell Jr. Children’s Hospital at Vanderbilt. “Although mortality was rare, our findings emphasize the significant illness caused by RSV in young infants.” Children with a history of prematurity or certain underlying medical conditions such as congenital heart disease, neurologic or neurodevelopmental/neuromuscular disorders, chronic lung disease and immunocompromising conditions are at higher risk for life-threatening RSV disease, according to Halasa and co-corresponding author Angela Campbell, MD, MPH, from the CDC. High-risk infants are the only eligible population approved to receive a monoclonal antibody to prevent RSV-associated LRTI called palivizumab. However, most infants in our study admitted to the ICU with severe RSV did not have an underlying medical condition. Therefore, our data support the need for RSV preventative interventions targeting all infants to reduce the burden of severe RSV illness, including nirsevimab, the long-acting RSV-neutralizing monoclonal antibody. The drug was recently approved by the Food and Drug Administration, and a maternal vaccine for RSV prevention is under consideration.” Natasha Halasa, MD, MPH, Craig Weaver Professor of Pediatrics in the Division of Pediatric Infectious Diseases at Monroe Carell Jr. Children’s Hospital at Vanderbilt Related Stories “These products may protect both high-risk and healthy infants from medically attended RSV-associated LRTI.” On Aug. 3, the Advisory Committee on Immunization Practices (ACIP) unanimously recommended nirsevimab for all infants younger than 8 months, born during or entering their first RSV season and for children ages 8-19 months who are at increased risk of severe RSV disease and entering their second RSV season. Additionally, ACIP unanimously recommended inclusion of nirsevimab in the Vaccines for Children program. The current study found that only 2 of 17 infants eligible for palivizumab received the treatment, which highlights administration barriers and emphasizes the need to ensure that all eligible patients receive therapeutic interventions in a timely manner. Since nirsevimab requires only one shot versus monthly shots, it is believed that uptake and compliance will be improved. “We hope that our study findings will aid in the design of future RSV prophylactic and maternal RSV vaccine effectiveness and usage studies and recommendations,” Halasa said. The study was supported by the CDC. Vanderbilt University Medical Center Journal reference: Halasa, N., et al. (2023). Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak. JAMA Network Open. doi.org/10.1001/jamanetworkopen.2023.28950.

Pregnancy diets and DNA: Nourishing the next generation

ByZarafshan Shiraz, New Delhi Aug 18, 2023 12:53 PM IST Share Via Copy Link The adage “you are what you eat” might be more profound than ever during pregnancy. Nutrition expert shares pregnancy diet plan to nourish the next generation Pregnancy can be a whirlwind of anticipation and preparation but amid the excitement, it is important not to forget the role of a well-balanced diet. The adage “you are what you eat” might be more profound than ever during pregnancy but nutrition isn’t just fuelling mom-to-be, it is laying the foundation for the baby’s lifelong health. Pregnancy diets and DNA: Nourishing the next generation (Photo by Mediamodifier on Unsplash) In an interview with HT Lifestyle, Deepika Suresh, Genomics Specialist and Chief of Staff at Xcode Life, shared, “A mother’s choices while pregnant can echo throughout the child’s life. It’s a truth that’s been whispered down the generations, from mother to child, but only recently has science confirmed its gravity. An eye-opening example comes from the Dutch famine of 1944-1945 during World War II, when food was scarce and pregnant women subsisted on a meagre 400-800 calories per day. Research conducted on children conceived during this period revealed they were at a higher risk of developing conditions like obesity and type 2 diabetes in adulthood. The effects of the famine were even observed at the genetic level, with modifications in DNA chemical prints, which resulted in the “silencing” of genes involved in energy utilization and fat and glucose breakdown. This contributed to unhealthy changes in how their bodies functioned.” These startling revelations are part of a growing field of study known as nutrigenomics and it’s a mouthful, sure but it’s a term that describes how our nutrition interacts with our genes to shape our health. Genes regulate the nutritional outcome of the food we eat and our diet influences how well our genes function. Deepika Suresh explained, “While the genetics of a baby is determined at the time of conception, their epigenetics keep evolving. Epigenetics? Think of it as tiny switches that can turn genes on or off. What controls these switches? Well, largely your diet. An optimal diet keeps the good, protective genes “on” and the bad, disease-prone genes “off.” So, one can say that what the mother eats while pregnant can make or break the child’s health. Increasing evidence demonstrates that children born to mothers who consumed a calorie-dense Western diet during pregnancy were at higher risk for type 2 diabetes. Deficiencies in micronutrients have been associated with neurodevelopmental issues. Lack of vitamin B9, vitamin B12, zinc, and iodine, common with vegetarian and vegan diets, can harm brain development. These deficiencies can lead to conditions like neural tube defects and developmental disorders. Studies have shown that if mothers take supplements for these nutrients during pregnancy, especially early on, it can decrease the risk of neurodevelopmental disorders in their children, including autism, ADHD, and even schizophrenia. So, a mother’s diet significantly affects the risk of these disorders in their offspring.” Now that we know maternal nutrition holds the key to the child’s health, what is the optimal pregnancy diet? Deepika Suresh answered, “Genes play a crucial role in shaping how your body reacts to certain types of food. This also applies when you’re pregnant. Let’s dive in with a few examples. Consider the MTHFR gene; it helps transform folate (vitamin B9) from your food into a form your body can use. If you have a certain variant, you might need more folate-rich foods or supplements to prevent possible congenital disabilities. This is why most doctors prescribe folic acid supplements to those pregnant or planning a pregnancy. Iron is an essential nutrient, especially during pregnancy, as it aids in delivering oxygen to the baby. Some people, however, have a variant in the HFE gene, which can cause the body to absorb too much iron. Along with the increased risk of maternal complications, it can also lead to growth problems in the fetus and congenital abnormalities.” She elaborated, “The FADS1 gene is also a crucial player in shaping pregnancy diet. It helps convert the good fats from plant sources like flaxseeds and walnuts into a usable form beneficial to the body. This is an important process, as good fats are crucial building blocks for fetal brain development. If you have a variant in this gene, it is important to get your good fats through animal sources like fish or consider nutritional supplements. To say it simply, there is no “one-size-fits-all” pregnancy diet. The time-honored advice on pregnancy diets, while useful, might not account for the intricate interplay between food, our genes, and our health. These insights into nutrigenomics highlight the importance of personalised dietary recommendations for pregnant women. The better we understand the relationship between genes and nutrition, the better we can protect the health of future generations.” Topics Nutrition Pregnancy Pregnant Women Woman Diet Fitness Health Dna

White Plains Hospital and Montefiore Bring Pediatric Specialty Care to White Plains

With a new office dedicated to specialty conditions in children, White Plains Hospital and Montefiore commit to expanding pediatric care in Westchester. Advanced pediatric care in Westchester became more convenient with the opening of the new Montefiore Pediatric Specialty practice. Pediatric cardiologists, pediatric gastroenterologists, pediatric surgeons, a pediatric rheumatologist and a pediatric nephrologist from the renowned Children’s Hospital at Montefiore (CHAM) are now seeing patients at 33 Davis Avenue in White Plains. Unlike general pediatricians, pediatric subspecialists are the only physicians uniquely qualified to diagnose, treat, and manage infants, children and adolescents with specialized complex, chronic conditions. They also focus on the developmental and emotional needs of children and adolescents, which can be different from those of adults. “Having access to advanced pediatric care, closer to home, is so important for families,” says Frances Bordoni, Executive Vice President for Ambulatory and Physician Services and Business Development at White Plains Hospital. “Montefiore has some of the best pediatric specialists in the country. To bring these services to Westchester eliminates barriers and heightens peace of mind for families who no longer have to scramble to get their children the care they need.” Through its partnership with Montefiore Einstein and CHAM, which has long been recognized as one of the nation’s best pediatric hospitals by U.S. News & World Report, White Plains Hospital enhances its pediatric specialty care in several critical areas with the addition of nationally recognized specialists who are leaders in their respective fields and actively engaged in clinical research to advance their respective specialties. CHAM’s Pediatric Heart Center is a world leader in advanced cardiovascular care for patients of all ages, from newborns to adults with congenital heart diseases. Pediatric cardiologist Dr. Daphne Hsu is one of the nation’s leading experts in children’s heart failure and heart transplantation. In addition to caring for pediatric and adult patients with congenital heart disease, Dr. Hsu conducts ongoing clinical research and is a nationally recognized pediatric cardiologic thought leader. For children with gastrointestinal conditions, liver disease, or nutritional concerns, CHAM offers one of the leading pediatric gastrointestinal (GI) programs in the nation, led by Dr. John F. Thompson. Dr. Thompson specializes in short bowel syndrome, Crohn’s disease, ulcerative colitis, celiac disease, eosinophilic esophagitis, feeding disorder, and chronic abdominal pain. Dr. Thompson is also the director of the Intestinal Rehabilitation Program at CHAM. His research focuses on ways to improve the lives and outcomes of children who have intestinal failure and short bowel syndrome. In addition, pediatric gastroenterologist Dr. Gitit Tomer leads CHAM’s Inflammatory bowel disease (IBD) program, which is dedicated to providing excellent care and improving the health and quality of life of patients with inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). IBD are chronic relapsing inflammatory gastrointestinal diseases causing severe diarrhea abdominal pain and weight loss that can lead to life-threatening complications. CHAM also offers nationally-recognized care for pediatric patients with kidney conditions. Dr. Frederick Kaskel, an internationally recognized expert in pediatric nephrology, who specializes in the treatment of kidney disorders in infants, children and adolescents and in end-stage kidney replacement therapy and transplantation, is Chief Emeritus of its Division of Pediatric Nephrology. The Ira Greifer Children’s Kidney Center includes New York state’s first dedicated pediatric dialysis facility. “We are delighted to enhance access to our team of pediatric subspecialists, many of whom have raised their own children in Westchester. No matter the symptom, condition or question, our team is ready to care for children and families in need of sophisticated specialty care at the Davis Avenue location,” said Michael D. Cabana, MD, MPH, Physician-in-Chief, The Children’s Hospital at Montefiore and The Michael I. Cohen, MD, University Chair, Department of Pediatrics, Albert Einstein College of Medicine. To make an appointment at the Montefiore Pediatric Specialty office, call 914-849-KIDS (5437). The providers seeing patients at 33 Davis Avenue include: Pediatric Cardiologist Daphne Hsu, MD Pediatric Gastroenterologists Inessa Normatov, MDJohn Thompson, MDGitit Tomer, MD Pediatric Nephrologist Frederick J. Kaskel, MD Pediatric Rheumatologist Tamar Rubinstein, MD Pediatric Surgeons Steven H. Borenstein, MDAlexandre N. Darani, MDDominique M. Jan, MD

Why Zika Virus in news?

Zika virus, initially identified in Uganda in 1947, is primarily transmitted by Aedes mosquitoes, which are active during the day. While many infections are asymptomatic, those who show symptoms typically experience rash, fever, conjunctivitis, muscle and joint pain, malaise, and headache for around 2-7 days. Pregnancy and Microcephaly Zika infection during pregnancy can lead to microcephaly and congenital malformations in infants. Congenital Zika syndrome encompasses clinical features like limb contractures, high muscle tone, eye abnormalities, and hearing loss. Roughly 5-15% of infants born to Zika-infected mothers exhibit related complications, including those resulting from asymptomatic infections. Neurological Complications Zika virus is also linked to Guillain-Barré syndrome, neuropathy, and myelitis, predominantly in adults and older children. Ongoing research investigates these neurological effects and their impact on pregnancy outcomes. Epidemiology and History From sporadic infections in Africa and Asia during the 1960s-1980s, Zika outbreaks emerged globally from 2007. The virus’s association with microcephaly and neurological disorders gained attention with the epidemic in Brazil in 2015. The World Health Organization (WHO) declared Zika-related microcephaly a Public Health Emergency of International Concern in February 2016, with confirmation of the causal link. Global Trends While Zika cases decreased globally after 2017, low-level transmission persists in parts of the Americas and other endemic areas. The virus also spread to Europe and India. Notably, 89 countries and territories have reported mosquito-transmitted Zika infection, yet global surveillance remains limited. Transmission and Diagnosis Aedes mosquitoes, particularly Aedes aegypti, primarily transmit Zika virus in tropical and subtropical regions. Transmission can also occur through maternal-fetal transfer, sexual contact, blood transfusion, and possibly organ transplantation. Diagnosis relies on laboratory tests due to cross-reactivity with related flaviviruses like dengue. Treatment and Prevention No specific treatment exists for Zika virus infection. Symptomatic patients are advised to rest, hydrate, and manage symptoms with antipyretics and analgesics. Pregnant women in transmission areas should seek medical care for testing, information, and counseling. Prevention hinges on avoiding mosquito bites through clothing, window screens, repellents, and nets. Eliminating mosquito breeding sites and controlling vectors are also crucial. No Zika vaccine is available, but research continues in this area. Prevention of Sexual Transmission Sexual transmission can occur, necessitating counseling for individuals with Zika virus infection and their partners. Safer sex practices, condom use, and contraceptive options are recommended to mitigate risks, especially for pregnant women. WHO’s Response The WHO supports countries in outbreak confirmation, offers technical guidance on managing mosquito-borne diseases, develops tools and strategies, provides training, and publishes guidelines for member states to enhance surveillance, diagnosis, and control of Zika virus. Find More Miscellaneous News Here

Bone Grafts and Substitutes Market Unlocking Potential: Share, Size, Segmentation Analysis, Key Segments, and Forecast 2031

The global bone grafts & substitutes market was valued at $2,652.6 million in 2020, and is projected to reach $3,362.6 million by 2028, registering a CAGR of 4.3% from 2021 to 2028. Rise in incidences of musculoskeletal disorders, development of biocompatible synthetic bone grafts, technological advancements in medical field leading to a shift from autograft to allograft drive the growth of the bone grafts & substitutes market. For instance, as per the data published by World Health Organization (WHO), in 2021, musculoskeletal conditions are the prominent contributors to disability globally, with low back pain being the single primary cause of disability in 160 countries or early deaths. Low back pain causes the greatest burden with a prevalence of 568 million people and this trend is expected to continue for next few years. Bone grafts are implantable materials that promote bone healing through its osteoconductive, osteogenic, and osteoinductive mechanisms. The bone grafts are used in surgical procedures such as spinal fusion surgeries, bone replacement, ensuring new bone formation, and repair of bone fractures. Moreover, bone grafting has applications in the treatment of various bone related disorders such as congenital pseudoarthrosis, dental bone grafting problems, and complex fractures. Allografts, synthetic bone grafts, and demineralized bone matrix are the most commonly used bone grafts worldwide. Download Free Sample of This Strategic Report: https://reportocean.com/industry-verticals/sample-request?report_id=AMR1795 In addition, increase in cases of lifestyle disorders such as diabetes and obesity add to the risk of developing degenerative joint diseases that further fuel the growth of the market. For instance, according to IDF Diabetes Atlas, Ninth Edition 2019, approximately 463 million adults had diabetes and by 2045, the number is estimated to increase to 700 million across the world. Apart from this, more than 1.1 million children were suffering from type 1 diabetes in 2019, which reveals the severity of this disease. Increase in incidences of diabetic cases leading to degenerative joint disorders is expected to provide high market growth and opportunities in near future. On the other hand, high cost of surgeries and ethical issues related with bone grafting procedures restrict the market growth. Conversely, emerging markets, rise in interests of key players toward R&D activities in bone grafts and its substitutes, and increase in demand for orthopedic procedures particularly in geriatric population are expected to provide profitable opportunities for the growth of the market in near future. The research report categorizes the bone graft & substitute market based on product type, application, and region. By product type, it is classified into allografts, bone grafts substitutes, and cell-based matrices. The allografts are further categorized to machined allografts and demineralized bone matrix. The bone graft substitutes segment is further classified into bone morphogenic proteins (BMP) and synthetic bone grafts. By application, it is divided into spinal fusion, trauma, craniomaxilofacial, joint reconstruction, and dental bone grafting. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The healthcare sector is vital to both national economies and people all across the world. One of the industries with the fastest growth rates is this one. There is a correlation between income levels and healthcare spending across nations because healthcare spending accounts for more than 10% of the GDP of the majority of developed countries. According to the Centers for Medicare and Medicaid Services, US healthcare spending increased by 4.6% in 2019 to reach US$ 3.8 trillion, or US$ 11,582 per person and represented 17.7% of GDP. Additionally, households paid for 28.4% of all health expenditures, followed by the federal government for 29.0%. 16.1% of all healthcare costs were paid for by state and municipal governments, while 7.5% came from other private sources. Download Free Sample of This Strategic Report: https://reportocean.com/industry-verticals/sample-request?report_id=AMR1795 Due to advancements spurred by AI/ML, the impact of digital health technology will grow. Data from the Department for Promotion of Industry and Internal Trade show that FDI in the medicines and medication sector totaled US$19.12 billion (DPIIT). KEY BENEFITS FOR STAKEHOLDERS ? The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.? The report provides a quantitative analysis for the period of 2021-2028 to enable stakeholders to capitalize on the prevailing market opportunities.? Extensive analysis of the market based on products helps understand the type of devices used to treat musculoskeletal disorders and degenerative joints diseases.? Competitive intelligence highlights the business practices followed by leading players across various regions.? Comprehensive analysis of all geographic regions helps determine the prevailing opportunities in these regions.? Key market players and their strategies are analysed to understand the competitive outlook of the overall market.? Extensive analysis of the market is conducted by following key product positioning and monitoring the top contenders within the market framework. KEY MARKET PLAYERS– Arthrex, Inc.– Baxter International Inc.– Integra LifeSciences Holdings Corporation– Johnson & Johnson ( DePuy Synthes )– Medtronic Plc.– Musculoskeletal Transplant Foundation– NuVasive, Inc.– Stryker Corporation– Xtant Medical Holdings, Inc.– Zimmer Biomet Holdings, Inc. KEY MARKET SEGMENTSBy Product– Allograftso Machined allograftso Demineralized bone matrix– Bone Grafts Substituteso Bone morphogenic proteins (BMP)o Synthetic bone grafts– Cell based matrices Request To Download Sample of This Strategic Report:- https://reportocean.com/industry-verticals/sample-request?report_id=AMR1795 By Application– Spinal fusion– Trauma– Craniomaxillofacial– Joint reconstruction– Dental bone grafting By Region– North Americao U.S.o Canadao Mexico– Europeo Germanyo Franceo UKo Italyo Spaino Rest of Europe– Asia-Pacifico Japano Chinao Indiao Australiao South Koreao Rest of Asia-Pacific– LAMEAo Brazilo South Africao Saudi Arabiao Rest of LAMEA Table of Content: Report Overview Global Growth Trends Competition Landscape by Key Players Data Segments North America Market Analysis Europe Market Analysis Asia-Pacific Market Analysis Latin America Market Analysis Middle East & Africa Market Analysis Key Players Profiles Market Analysis Analysts Viewpoints/Conclusions Appendix Reasons to Buy This Report: This file will help the peruses with appreciation the opposition interior the ventures and structures for the serious local weather to improve the feasible benefit. The document moreover facilities round the cutthroat scene of the market, and provides exhaustively the piece of the pie, industry positioning, contender organic system, market execution, new